|Day Low/High||111.44 / 112.53|
|52 Wk Low/High||94.28 / 126.07|
Attorney Mark Lanier: Third MDL bellwether trial sends strong message
Jim Cramer is watching Johnson & Johnson, which may buy a Swiss drugmaker. Cramer says it's important to see how the deal is structured.
European stocks ended Tuesday's session with modest gains, although the FTSE 100 drifted lower amid the global oil selloff.
This stock needs more aggressive buying before it is an outright long.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
Oil prices tumble Tuesday on doubts that OPEC can reach an agreement to cut production; U.S. stock futures point to a mild rebound for Wall Street.
European stocks were mixed across the region but improving U.S. futures prices could turn the Tuesday tide.
Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.
U.S. stock futures point lower as crude oil gyrates after Saudi Arabia pulls out of a meeting Monday with Russia and other large non-OPEC producers.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
Johnson & Johnson has some of the world's best-known health and personal care brands, while Actelion manufactures popular treatments for pulmonary arterial hypertension.
This health care stalwart is a rare combination of growth and income. Here's why now's the time to scoop it up.
European markets closed higher for the third week running, led by Johnson & Johnson target Actelion, while oil contractors fell along with the price of Brent crude oil.
Wall Street hit new highs on Friday in a half-day session after the Thanksgiving holiday.
Stocks edge higher on Friday, on track to post another record session, in a quieter session after the Thanksgiving holiday in the U.S.
Stock futures edge higher on Friday, on track to post another record session, in a quieter session after the Thanksgiving holiday.
Target sees a surge in online traffic on Thanksgiving; U.S. stock futures suggest the Dow will open at another record high; J&J reportedly is bidding for Switzerland's Actelion.
Technical support and statistical evidence suggest the stock will rebound.
President-elect Donald Trump vowed to repeal the Trans-Pacific Partnership and overhaul the United States' relationship with trade partners like China and Mexico.
Since its powerful post-election breakout, Johnson & Johnson has been under steady pressure.
Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.
Endowed Chair at Whitehead Institute Honors Legacy of Globally Renowned Researcher and Champion for Women in Science
Cramer shares his views on the world of unknowns. Starbucks, General Electric and Pfizer are among the stocks discussed.
Cramer shares his views on looking at oil now that the election is over. Starbucks, Kellogg and PepsiCo are among the stocks discussed.
Jim Cramer takes a moment to honor American veterans, and the companies who are working to support them.
Johnson & Johnson CEO Alex Gorsky says veterans are critical to company's success.
Jim Cramer honors veterans and those willing to invest in a brighter future for America.